| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Molecular Immunology Group Nuffield Department of Medicine, and
Imperial Cancer Research Foundation, Institute of Molecular Medicine, and
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom;
Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany;
¶ Institute of Research in Biomedicine, Bellinzona, Switzerland; and
||
Skin Tumor Unit, St. John’s Institute of Dermatology, St. Thomas’ Hospital, Westminster, London, United Kingdom
In a significant proportion of melanoma patients, CTL specific for the melan-A26/7–35 epitope can be detected in peripheral blood using HLA-A2/peptide tetramers. However, the functional capacity of these CTL has been controversial, since although they prove to be effective killers after in vitro expansion, in some patients they have blunted activation responses ex vivo. We used phenotypic markers to characterize melan-A tetramer+ cells in both normal individuals and melanoma patients, and correlated these markers with ex vivo assays of CTL function. Melanoma patients with detectable melan-A tetramer+ cells in peripheral blood fell into two groups. Seven of thirteen patients had a CCR7+ CD45R0- CD45RA+ phenotype, the same as that found in some healthy controls, and this phenotype was associated with a lack of response to melan-A peptide ex vivo. In the remaining six patients, melan-A tetramer+ cells were shifted toward a CCR7- CD45R0+ CD45RA- phenotype, and responses to melan-A peptide could be readily demonstrated ex vivo. When lymph nodes infiltrated by melan-A-expressing melanoma cells were examined, a similar dichotomy emerged. These findings demonstrate that activation of melan-A-specific CTL occurs in only some patients with malignant melanoma, and that only patients with such active immune responses are capable of responding to Ag in ex vivo assays.
This article has been cited by other articles:
|
|
 |
|
  V. Voelter, N. Rufer, S. Reynard, G. Greub, R. Brookes, P. Guillaume, F. Grosjean, T. Fagerberg, O. Michelin, S. Rowland-Jones, et al. Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor Int. Immunol., August 1, 2008; 20(8): 1087 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Ling, N. Dulphy, P. Bahl, M. Salio, K. Maskell, J. Piris, B. F. Warren, B. D. George, N. J. Mortensen, and V. Cerundolo Modulation of CD103 Expression on Human Colon Carcinoma-Specific CTL J. Immunol., March 1, 2007; 178(5): 2908 - 2915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes J. Immunol., November 1, 2006; 177(9): 6081 - 6090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Smith, F. Mirza, V. Pasquetto, D. C. Tscharke, M. J. Palmowski, P. R. Dunbar, A. Sette, A. L. Harris, and V. Cerundolo Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara J. Immunol., December 15, 2005; 175(12): 8431 - 8437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wei, I. Kryczek, L. Zou, B. Daniel, P. Cheng, P. Mottram, T. Curiel, A. Lange, and W. Zou Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma Cancer Res., June 15, 2005; 65(12): 5020 - 5026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance Cancer Res., April 15, 2004; 64(8): 2865 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Atanackovic, A. Block, A. de Weerth, C. Faltz, D. K. Hossfeld, and S. Hegewisch-Becker Characterization of Effusion-Infiltrating T Cells: Benign versus Malignant Effusions Clin. Cancer Res., April 15, 2004; 10(8): 2600 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mallard, F. Vernel-Pauillac, T. Velu, F. Lehmann, J.-P. Abastado, M. Salcedo, and N. Bercovici IL-2 Production by Virus- and Tumor-Specific Human CD8 T Cells Is Determined by Their Fine Specificity J. Immunol., March 15, 2004; 172(6): 3963 - 3970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses J. Immunol., February 1, 2004; 172(3): 1380 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases Cancer Res., January 1, 2004; 64(1): 406 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Butterfield, A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, et al. T-Cell Responses to HLA-A*0201 Immunodominant Peptides Derived from {alpha}-Fetoprotein in Patients with Hepatocellular Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5902 - 5908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Salio, N. Dulphy, J. Renneson, M. Herbert, A. McMichael, A. Marchant, and V. Cerundolo Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells Int. Immunol., October 1, 2003; 15(10): 1265 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. J. Schreurs, K. B. J. Scholten, E. W. M. Kueter, J. J. Ruizendaal, C. J. L. M. Meijer, and E. Hooijberg In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones J. Immunol., September 15, 2003; 171(6): 2912 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pittet, V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J.-C. Cerottini, P. Romero, and A. Zippelius {alpha}3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells J. Immunol., August 15, 2003; 171(4): 1844 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Anichini, A. Scarito, A. Molla, G. Parmiani, and R. Mortarini Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common {gamma}-Chain Cytokines J. Immunol., August 15, 2003; 171(4): 2134 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Bohula, A. J. Salisbury, M. Sohail, M. P. Playford, J. Riedemann, E. M. Southern, and V. M. Macaulay The Efficacy of Small Interfering RNAs Targeted to the Type 1 Insulin-like Growth Factor Receptor (IGF1R) Is Influenced by Secondary Structure in the IGF1R Transcript J. Biol. Chem., April 25, 2003; 278(18): 15991 - 15997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ayyoub, A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J.-C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D. E. Speiser Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1 Clin. Cancer Res., February 1, 2003; 9(2): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mantovani, B. Palermo, S. Garbelli, R. Campanelli, G. Robustelli della Cuna, R. Gennari, F. Benvenuto, E. Lantelme, and C. Giachino Dominant TCR-{alpha} Requirements for a Self Antigen Recognition in Humans J. Immunol., December 1, 2002; 169(11): 6253 - 6260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Peng, J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Shu, and P. A. Cohen Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy J. Immunol., November 1, 2002; 169(9): 4811 - 4821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going? J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Sutton and J Neuberger Primary biliary cirrhosis: seeking the silent partner of autoimmunity Gut, June 1, 2002; 50(6): 743 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Palmowski, E. M.-L. Choi, I. F. Hermans, S. C. Gilbert, J.-L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, et al. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols J. Immunol., May 1, 2002; 168(9): 4391 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zippelius, M. J. Pittet, P. Batard, N. Rufer, M. de Smedt, P. Guillaume, K. Ellefsen, D. Valmori, D. Lienard, J. Plum, et al. Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans J. Exp. Med., February 19, 2002; 195(4): 485 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Perez-Diez, P. J. Spiess, N. P. Restifo, P. Matzinger, and F. M. Marincola Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance J. Immunol., January 1, 2002; 168(1): 338 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Speiser, M. Colonna, M. Ayyoub, M. Cella, M. J. Pittet, P. Batard, D. Valmori, P. Guillaume, D. Lienard, J.-C. Cerottini, et al. The Activatory Receptor 2B4 Is Expressed In Vivo by Human CD8+ Effector {alpha}{beta} T Cells J. Immunol., December 1, 2001; 167(11): 6165 - 6170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Blanchet, D. Valmori, I. Dufau, M. Ayyoub, C. Nguyen, P. Guillaume, B. Monsarrat, J.-C. Cerottini, P. Romero, and J. E. Gairin A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy J. Immunol., November 15, 2001; 167(10): 5852 - 5861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Salio, D. Shepherd, P. R. Dunbar, M. Palmowski, K. Murphy, L. Wu, and V. Cerundolo Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC J. Immunol., August 1, 2001; 167(3): 1188 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pittet, A. Zippelius, D. E. Speiser, M. Assenmacher, P. Guillaume, D. Valmori, D. Lienard, F. Lejeune, J.-C. Cerottini, and P. Romero Ex Vivo IFN-{{gamma}} Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases J. Immunol., June 15, 2001; 166(12): 7634 - 7640. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
